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Mitochondria are the centre of metabolism in cells, coupling the
oxidation of substrates to ATP synthesis by an electrochemical proton
gradient. Varying this protonmotive force allows for adjustments in
energy metabolism to maintain metabolic homeostasis. For this
reason, the coupling of substrate oxidation is incomplete, as protons
can leak across the mitochondrial inner membrane independently of
ATP production. This unregulated futile proton conductance is of
considerable physiological relevance, as it can account for as much as
20–70% of cellular metabolic rate depending on cell type [1,2]. A
majority of proton leak can be strictly attributed to the abundance, but
not activity, of mitochondrial carrier proteins such as the adenine
nucleotide translocase (ANT) and, in brown adipose tissue (BAT),
uncoupling protein 1 (UCP1) [3,4].
Importantly, the regulation of proton leak allows for responses to
ﬂuctuations in energy demands and controls energy transduction to
maintain cellular homeostasis and body function. The ﬁrst proton leakmechanism was identiﬁed in BAT, where UCP1-catalysed proton
conductance generates heat to defend body temperature during cold
acclimation [5]. Sequence similarity allowed the identiﬁcation of its
paralogous proteins UCP2 and UCP3 [6,7]. These UCPs do not contribute
to basal proton conductance in vitro in the absence of speciﬁc activators
[8].When activated, however, all UCPs (including avian and plant UCPs)
can catalyse proton leak [9]. The precise mechanisms of activation and
inhibition of both UCP2 and UCP3, as well as their physiological role,
remain uncertain [10,11]. There has been considerable recent progress,
however, in understanding the transcriptional and translational
regulation that implicates UCP2 and UCP3 in adaptation to nutritional
status and oxidative stress. More recently, the unique dynamic
regulation of UCP2 reveals a new mechanism for the regulation of
mitochondrial energy metabolism by the novel UCPs.
2. Acute activation of uncoupling protein activity
UCP1 activity is highly regulated at the molecular level by small
molecules. It is inhibited by physiological concentrations of purine
nucleoside di- and tri-phosphates and stimulated when fatty acids
overcome nucleotide inhibition [12].
How fatty acids activate the net protonophoric activity of UCP1 is still
debated. Broadly, there are three models that can explain the
dependence on fatty acids. In the ﬁrst, fatty acids act as co-factors by
embedding their carboxyl groups in the core of the protein to bind and
release protons as they access amino acid side chains during transport
[13]. Evidence that UCP1 can translocate chloride and fatty acid anions
suggests a second model. In this mechanism, protonated fatty acids
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promotes their dissociation into fatty acid anions in the matrix, and the
fatty acid anions are then exported fromthematrix byUCP1 [14]. Thenet
activity results in proton conductance across the inner membrane,
though in this model UCP1 itself does not translocate protons. Thirdly,
fatty acids themselvesmaynot bedirectly required for UCP1 activity, but
instead act as allosteric activators by promoting a conformation of the
protein that is protonophoric (or that translocates hydroxide ions), since
fatty acids and nucleotides appear to affect proton conductance in a
manner described by simple competitive kinetics [15,16].
It remains unclear to what extent UCP2 and UCP3 are subject to the
same acute molecular regulation as UCP1 (and the extent to which
they share the same mechanism of uncoupling). Although they lack
sequence homology in a matrix-localised region reportedly critical for
fatty acid activation of UCP1 [17], proteoliposome studies show that
UCP2 and UCP3 have similar fatty acid-activated proton conductance
and purine nucleotide inhibition as UCP1 [18–20]. One difﬁculty has
been the inability to directly compare UCPs in mitochondria, since
UCP2 and UCP3 are expressed in different tissues and at hundred-fold
lesser amounts than UCP1 [21–23]. Another difﬁculty relates to the
fact that GDP has been shown to inhibit uncoupling via ANT [24,25] as
well as by the UCPs. This complicates the calculations of UCP-
mediated proton leak in tissues that express different amounts of UCP
and ANT when activity is deﬁned as GDP-sensitive uncoupling.
There is evidence that superoxide, both exogenous [26] and
endogenous [27], and lipid peroxidation products such as hydro-
xynonenal [25,28,29] can activate uncoupling by all three UCPs,
suggesting a model in which superoxide reacts with membrane
phospholipids to generate the proximal activator, hydroxynonenal
[28,30]. The physiological relevance of this model, which has not been
reproduced in all laboratories, remains controversial [10,31–33].
3. Role and regulation of uncoupling proteins
The archetypal uncoupling protein, UCP1, is best known for its role
in adaptive non-shivering thermogenesis and control of body weight,
whereby a cold stimulus or over-feeding results in sympathomimetic
stimulation of β3-adrenergic receptors in BAT. This leads to upregula-
tion of Ucp1 mRNA expression via a BAT-speciﬁc enhancer box [34],
activation of UCP1 by fatty acids [35] produced from lipolysis [36], and
the transduction of the mitochondrial protonmotive force into heat
[37]. Indeed Ucp1 knockout results in the absence of non-shivering
thermogenesis [38], loss of cold tolerance [39] and appearance of
obesity at thermoneutrality [40]. Beyond thermogenesis, the role of
UCP1 in thymus [41,42] and in ectotherms [43] remains speculative.
The UCP1 paralogues, UCP2 and UCP3, probably evolved from a
duplication event in vertebrates. This is supported by their juxtapo-
sition in the genome and their high sequence identity with each other
(72–74% from ﬁsh to mammals). Sequence analysis shows that unlike
UCP1, UCP2 and UCP3 are under strong purifying selection, suggesting
that they have not changed function during evolution [44].
The literature varies on whether or not UCP2 and UCP3 are
upregulated in response to cold in various organisms and tissues [45–
47], but they are not thought to be signiﬁcantly thermogenic [48],
primarily because of their low abundance. However, rodent UCP3 can
participate in thermogenesis under particular conditions [49,50].
UCP2 and UCP3 are also upregulated in response to starvation, and
have been linked with a number of processes including insulin
secretion from pancreatic β-cells [51] and insulin resistance [52] in
peripheral tissues, as well as modulation of reactive oxygen species
production and immune responses [10,53–55].
3.1. UCP2 function
An ever-increasing number of studies highlight the signiﬁcance of
UCP2 in a broad range of physiological and pathological processes,including cytoprotection [55–58], immune cell modulation [53,59]
as well as the regulation of glucose sensing in the brain [60] and
pancreas [51].
In thymocytes [61] and the intact INS-1E pancreatic β-cell model
[62], UCP2 decreases the coupling between substrate oxidation and
ATP production. Since mitochondrial ROS production is highly
sensitive to decreases in protonmotive force [63–65], UCP2-mediated
dissipation of the mitochondrial membrane potential and pH gradient
results in decreased reactive oxygen species production [66,67],
particularly during reverse electron transport [65].
In glucose-sensing cells in the pancreas and brain, UCP2 attenuates
insulin secretion, likely acting in two ways. By lowering the coupling
efﬁciency of oxidative phosphorylation, UCP2 decreases the ATP/ADP
ratio, resulting in the decreased stimulation of KATP channels and
lowered insulin secretion [51,68]. It may also function by decreasing
ROS production [67], which is important signal in glucose-sensing
systems [69,70].
As well as improving the diabetic phenotype via increased insulin
secretion [51], UCP2 downregulation also improves insulin resistance
in peripheral tissues such as white adipose [71]. Although much work
indicates that UCP2 exacerbates the diabetic phenotype, recent work
from the Collins group suggests that this effect is dependent on
genetic background, and that the chronic absence of UCP2 causes
persistent oxidative stress in general and impairs β-cell function [72].
However, it is unlikely that these ﬁndings simply invalidate all
previous work demonstrating attenuation of glucose-stimulated
insulin secretion by UCP2. For example, acute in vivo knockdown of
UCP2 using antisense oligonucleotides in two animal models of
diabetes and insulin resistance causes a signiﬁcant improvement in
insulin secretion and enhanced whole-body sensitivity to insulin [73].
In the light of the cytoprotective effects conferred by UCP2, however,
Pi et al. [72] question the validity of the approach of inhibiting UCP2
function in order to improve glucose-stimulated insulin secretion in
diabetes [74]. Numerous studies have shown that by attenuating
oxidative stress, UCP2 promotes cell survival in pancreaticα- [58] and
β- [55] cells and in neurones [57], and can regulate colon tumour
formation [75] and atherosclerosis [56,76].
Newell and colleagues propose an interesting hypothesis in which
a cell's ability to efﬁciently metabolise fat confers immune privilege.
Speciﬁcally, they suggest that UCP2 is a part of the mechanism
controlling the change from one metabolic strategy (glucose
metabolism) to another (primarily lipid metabolism), and by doing
this, UCP2 plays a role in preventing immune-mediated pathology
[54,77]. This, of course, is in line with the cytoprotective effect of UCP2
described earlier. Bouillaud has recently proposed that this function
could be explained by a uniport for anionic pyruvate that lowers the
preference for pyruvate oxidation as membrane potential increases
[78]. However, this hypothesis has yet to be experimentally veriﬁed
and remains speculative.
3.2. Regulation of UCP2 concentration
UCP2 regulation occurs in a concerted manner by modulation of
protein activity and protein content. Ligands (such as fatty acids and
ROS derivatives) that stimulate UCP2 catalytic activity in isolated
mitochondria [11] may also play a role in upregulating UCP2 content
[79].
In hyperglycaemia and hyperlipidaemia, as occurs in diabetes
mellitus, Ucp2 gene transcription is activated by key regulatory
proteins such as peroxisome proliferator-activated receptors (PPARs),
forkhead transcription factors, and sterol regulatory element-binding
protein-1c (SREBP-1c) [80]. Sirt1, a protein that has been implicated
in metabolic stress resistance, suppresses the function of these
proteins, thus decreasing Ucp2 expression and promoting insulin
secretion [81]. Additionally, reactive oxygen species and their
products have been implicated in the upregulation of UCP2
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that decreases ROS production [82,83], although a direct interaction of
ROS with ROS-responsive elements upstream of UCPs has never been
demonstrated.
Ucp2 is also translationally regulated by an inhibitory upstream
open reading frame (ORF) [84], which, when mutated, results in
maximal Ucp2 mRNA translation [84]. Glutamine, an amino acid that
has been implicated in the insulin secretion pathway [85], overcomes
ORF inhibition and increases Ucp2 translation efﬁciency [86].
Recently we showed that in INS-1E pancreatic β-cells, UCP2 levels
are dynamically regulated in response to nutrient supply, and this
rapid ﬂuctuation in content is permitted by variable synthesis rates
coupled with rapid degradation [87]. Regulation of turnover is further
discussed in Section 4.
3.3. UCP3 function
UCP3 tissue-speciﬁcity has been maintained during evolution: it is
speciﬁc to skeletal muscle, although in mammals, notable protein
levels are also found in BAT [7].
In mammals, cold-induced expression initially led to the conclu-
sion that UCP3 may mediate thermogenesis in the same way as UCP1
[88]. However, the apparent upregulation during fasting and the lack
of change in body temperature of Ucp3-ablated mice argue for no
physiological thermogenic role for mammalian UCP3 [89,90]. None-
theless, there is evidence that UCP3may be involved in thermogenesis
of some description, albeit not as its main function. Nau et al. have
recently shown that a selective lack of UCP3 in BAT impairs non-
shivering thermogenesis [50]. Other evidence points to this role of
UCP3 in muscle: pharmacological intervention using the drug MDMA
(3,4-methylenedioxymethamphetamine) in Ucp3-ablated mice
results in a diminished thermogenic response [49]. These data do
not necessarily suggest that UCP3 is directly involved in thermogen-
esis, but that it may, by currently unknownmechanisms, be necessary
for the machinery that is. Additionally, there is a body of work
showing that increased UCP3 levels do not always result in increased
uncoupling [91], and work from our laboratory has reached the same
conclusion [92]. As changes in protein concentration do not
necessarily result in concomitant increases in protein activity [93],
caution is required when interpreting these data.
Protection from ROS has been suggested as a putative role for
UCP3. In this model, the protein can be activated with endogenous
[27] and exogenous superoxide [26] as well as lipid peroxidation
products [30], dissipating mitochondrial membrane potential and
decreasing ROS production [64]. This theory is supported by work
showing that UCP3 neutralises protein oxidation in skeletal muscle
[94] and may mitigate ROS production during exercise [95].
Furthermore, UCP3 knockout mice have higher oxidative damage
[96] and UCP3 over-expressing mice have reduced ROS production
during aging [97].
Other work has suggested that UCP3 is involved in fatty acid
metabolism. UCP3 over-expression has been shown to increase fatty
acid transport and oxidation [98]. The hypothesis that UCP3
physiologically functions as a fatty acid transporter [99,100] has
recently been refuted by Seifert et al., who found that whilst UCP3was
necessary for the fasting-induced enhancement of fatty acid oxidation
rate and capacity via mitigated mitochondrial oxidative stress, UCP3
was not itself a fatty acid transporter [101].
In addition to increased fatty acid oxidation and reduced ROS
production, UCP3 over-expressing mice also have decreased diet-
induced obesity [102] and are protected against insulin resistance.
Insulin resistance in peripheral tissues, in particular skeletal muscle, is
a major cause of type 2 diabetes mellitus [52]. Type 2 diabetes can be
promoted by obesity and aging, which on the cellular level broadly
equates to impaired fatty acidmetabolism and oxidative damage from
uncontrolled ROS production.PPAR agonists such as rosiglitazone have been successfully used to
treat insulin resistance. UCP3 expression is upregulated in response to
PPAR stimulation, and UCP3 has been suggested as a potential
therapeutic target to treat insulin resistance in skeletal muscle by
dissipating energy of fat storage. Treatment of human patients with
rosiglitazone upregulates UCP3 expression and improves insulin
resistance in diabetic patients [103]. Although this effect can be
explained by burning of excessive fats by mitochondrial uncoupling
[104], some groups suggest that this occurs via a mechanism other
than uncoupling [105,106], although the nature of this mechanism
remains unspeciﬁed.
3.4. Regulation of UCP3 concentration
Although non-mammalian UCP3 has not been investigated
extensively, fasting-induced gene expression appears conserved
among vertebrates from ﬁsh and birds to mammals [46].
Coordinated Ucp3 expression by fasting, cold, or high fat diet
requires transcription factor binding to the Ucp3 promoter region.
MyoD and PPAR elements are responsible for muscle speciﬁcity and
fatty acid responsiveness [107]. A region 1500 base pairs upstream
from the Ucp3 promoter that drives BAT-speciﬁc expression was
recently found [108]. A role for UCP3 in thyroid metabolism has also
been suggested [109] and, indeed, an active thyroid hormone
response element was identiﬁed in the proximal promoter region of
Ucp3 [110]. The stimulation of Ucp3 transcription by hormones that
regulate energy expenditure and fat metabolism in skeletal muscle
suggests (in line with other work) that UCP3 itself may also be
involved in these processes. Ucp3 transcription is well studied, but
nothing is known about Ucp3 mRNA translation efﬁciency. However,
similar to Ucp2, there are pseudo-start codons in the Ucp3 5′UTR that
can putatively trap ribosomes (MJ, unpublished data).
UCP3 activity can be further modulated via protein-protein
interactions, activating/inhibiting ligands and by proteolysis. Specu-
latively, stress-responsive genes such as those of the 14.3.3 family
have been implicated as having protein-protein interactions with
UCP2 and UCP3, but not with UCP1 [111]. Although the biochemical
signiﬁcance of this interaction remains sketchy, it raises the question
as to whether or how they are involved in UCP2 and UCP3 regulation.
Recently, we have made some headway in describing UCP3
turnover, which is more similar to UCP2 in half-life and mechanism
of degradation than it is to UCP1 (discussed in Section 4). A non-
exhaustive summary of UCP regulation is shown in Fig. 1.
4. Turnover of uncoupling proteins
Despite the fact that proteolysis is important in controlling overall
levels of any given protein, the issue of UCP half-life and turnover has
remained surprisingly neglected in the ﬁeld, being described well
over ten years after the discovery of each of the UCP homologues.
UCP1 half-life in BAT is in the order of hours to days and is
signiﬁcantly increased by administration of noradrenaline, which also
upregulates UCP1 synthesis [112]. However, the mechanism of
turnover remained uncertain until Desautels and colleagues showed
that the proteolytic rates of other mitochondrial proteins parallel
those for UCP1, and that the half-lives of UCP1 and other mitochon-
drial proteins are delayed by lysosomal inhibition [113,114].
The half-life and turnover mechanism of UCP1 differs from that
of its homologues UCP2 and UCP3. These both have unusually short
half-lives, which are at least an order of magnitude lower than that
for UCP1. UCP2 has a half-life of one hour in a range of tissues [83,115],
including pancreatic β-cell models [87]. We showed that this
rapid half-life is not a general feature of mitochondrial inner mem-
brane proteins like ANT, and is not recapitulated in isolated ener-
gised mitochondria, suggesting that an extramitochondrial factor
may be required for efﬁcient UCP2 degradation [87]. We further
Fig. 1.Mammalian UCP gene expression and activity is regulated at multiple steps. Stimuli such as cold and over-feeding activate sympathomimetic pathways that act on the UCP1
enhancer box (2.5 kb upstream), thereby increasing Ucp1 gene expression in BAT. These pathways also increase lipolysis resulting in fatty acids that stimulate UCP1 catalytic activity.
Inhibition of lysosomal pathways that degrade UCP1 also contribute to optimising UCP1-mediated thermogenesis. UCP2 appears in various tissues. Its gene expression is regulated
by various nutrients and cytokines/immunomodulators, which act via PPAR and SREBP at the transcription level. Translation efﬁciency is regulated by either the upstream ORF
or pseudo-start codons in the 5′UTR, and this region appears to be responsive towards glutamine. UCP3 is targeted to skeletal muscle by coordination of PPAR and theMyoD element.
A 1.5 kb upstream element controls BAT-speciﬁc expression. PPAR elements may transmit information about changes in fatty acid metabolism to Ucp3 gene expression. The
transcription factor ATF1 appears to regulate hypoxic-induced regulation of UCP3 while TREs mediate response to thyroid hormone. Translation efﬁciency has not been studied, but
there are pseudo-start codons in the 5′UTR, putatively trapping ribosomes. UCP2 and UCP3 (but not UCP1) are rapidly turned over by the cytosolic proteasome.
Fig. 2.Models of UCP2 degradation. In model A, UCP2 is ubiquitinated by an unidentiﬁed putative E3 ligase (A2) and unfolded from the mitochondrial inner membrane by processes
that may be ATP- or Δψ-dependent. At the mitochondrial outer membrane, the proteasome, perhaps tethered by FKBP8, recognises polyubiquitinated UCP2 (A4) and participates in
its extraction frommitochondria in an ATP-dependent fashion, whereby the protein is subsequently degraded by the peptidase activity of the proteasome core (A5). However, ﬁrstly
it remains unknown whether UCP2 can be ubiquitinated whilst still residing inside mitochondria: there are no known intramitochondrial E3 ligases, and it is widely believed that
mitochondrially associated E3 ligases reside in the outer membrane and ubiquitinate proteins on the cytosolic face of mitochondria. Secondly, the speculative nature of model A also
extends to the formation ofmitochondrial inner and outermembrane contact sites (A3). Since there is evidence that the proteasomemay be required for direct removal of UCP2 from
mitochondria [116], the contact site feature was modelled to describe how the cytosolic proteasome might gain access to UCP2 given the interposition of the mitochondrial outer
membrane. An alternativemodel B to explain the data from [116] is that amitochondrial process ejects UCP2 only as far out as themitochondrial outer membrane (B2), whereupon it
is ubiquitinated by cytosolic-facing outer membrane-associated E3 ligases (B3), then retrotranslocated by the proteasome (B4) before being degraded in the cytosol (B5).
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proteasomal machinery [116]. Use of proteasome inhibitors, ubiquitin
mutants and a novel cell-free reconstituted system showed that cy-
tosolic proteasomal function is required for rapid UCP2 degradation in
cells and in isolatedmitochondria [116]. How this cytosolicmachinery
accesses inner membrane residing UCP2 despite the interposition
of the mitochondrial outer membrane remains unknown, but our
working models of how this might be achieved are shown in Fig. 2.
Using the same techniques, we found that UCP3 also has a half-life
of between 1 and 4 h [117]. In contrast to UCP2 and UCP3, UCP1 and
ANT had much longer half-lives and could not be degraded in the cell-
free reconstituted system, suggesting their degradation is not
mediated by the cytosolic proteasome [117].
We postulate that this fast turnover allows for rapid variations in
UCP2 [87] and UCP3 levels in response to changes in nutrient ﬂuxes,
and the proteolytic pathway via the proteasome may allow the rapid
regulation of these proteins in concert with other proteins involved in
the same pathways. For example, in the pancreatic β-cell, the
ubiquitin-proteasome system is responsible for regulating levels of
other members of the insulin secretion pathway [118–120].
It is interesting to note that UCP1 protein levels are regulated by
modulation of the synthesis and degradation in a concerted fashion [121].
The question arises as to whether UCP2 and UCP3 levels are also
controlled in a concerted manner. Giardina et al. suggested that ROS not
only increase UCP2 transcription but may also slow degradation [83].
However, we showed that the latter is in fact a confounding observation
because only bioenergetic manipulations that increase ROS and simulta-
neously dissipate ATP and mitochondrial membrane potential result in
slowing of UCP2 turnover [116]. This is not entirely unexpected since the
proteasome-mediated degradation is ATP-dependent. Other thanmanip-
ulation of ATP and mitochondrial membrane potential, to date, we have
yet to ﬁnd conditions that affect the rate of UCP2 degradation.
Interestingly, the literature suggests that cellular proteolysis via
the proteasome increases under catabolic conditions [122], which
promote upregulation of UCP2 and UCP3. As such, UCP2 and UCP3
may be subject to constant rapid turnover, with variable expression
being dependent primarily on rates of synthesis. It would be
noteworthy to further examine whether regulators of UCP2 tran-
scription or translation can also inﬂuence turnover, as this remains an
alternative possibility.
5. Concluding remarks
There is abundant evidence that UCPs are important metabolic
regulators in permitting fat oxidation and in attenuating free radical
production. Their levels and activity are regulated by modulators of
cellular metabolism at multiple points, including transcription,
translation, modulation of catalytic activity and protein degradation.
Although UCP2 and UCP3 are not responsible for adaptive thermo-
genesis, they can, nevertheless be thermogenic when activated by
appropriate effectors. Their broad effects on coupling efﬁciency, ROS
production and fatty acid metabolism increasingly implicate them in
body-wide pathology and physiology, making them prospective drug
targets for the treatment of obesity, atherosclerosis, diabetes, immune
disorders and neurodegenerative conditions. Intricate knowledge of
UCP regulation and turnover, however, is only just beginning to
materialise, and much work is required before we are able to develop
therapies with maximal beneﬁt and minimal side effects.
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